Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068692 · ClinicalTrials.gov registry record · Phase 3
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
A Phase 3 study of Recurrent Rectal Carcinoma and Stage IIIA Rectal Cancer AJCC v7, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
- 1
- Study location
NCT00068692 is a Phase 3 study of Recurrent Rectal Carcinoma and Stage IIIA Rectal Cancer AJCC v7 that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 225 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00068692, a Phase 3 study of Recurrent Rectal Carcinoma and Stage IIIA Rectal Cancer AJCC v7, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized phase III trial is comparing the effectiveness of three adjuvant combination chemotherapy regimens in treating patients who are receiving radiation therapy and fluorouracil either before or after surgery for stage II or stage III rectal cancer. Drugs used in chemotherapy, such as irinotecan, fluorouracil, leucovorin, and oxaliplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which adjuvant combination chemotherapy regimen is more effective in treating patients who are receiving radiation therapy and fluorouracil either before or after surgery for rectal cancer.
Conditions Studied
Interventions
- DRUG Fluorouracil
- DRUG Oxaliplatin
- RADIATION Radiotherapy
- DRUG Irinotecan
- DRUG Leucovorin Calcium
Study Locations (1)
Massachusetts
- Eastern Cooperative Oncology Group - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2003-10-15 |
| Est. Completion | 2016-11-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068692
The ClinicalTrials.gov registry entry for NCT00068692 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Rectal Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Fluorouracil is the first listed.
NCT00068692 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00068692 about?
NCT00068692 is a clinical study titled "Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer". This randomized phase III trial is comparing the effectiveness of three adjuvant combination chemotherapy regimens in treating patients who are receiving radiation therapy and fluorouracil either before or after surgery for stage II or stage III rectal cancer. Drugs used in chemotherapy, such as iri...
What is the current status of trial NCT00068692?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2003-10-15. Estimated completion is 2016-11-15.
What conditions does trial NCT00068692 study?
This clinical trial studies the following conditions: Recurrent Rectal Carcinoma, Stage IIIA Rectal Cancer AJCC v7, Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Stage IIA Rectal Cancer AJCC v7.
What interventions are being tested in trial NCT00068692?
The interventions under investigation include: Fluorouracil (DRUG), Oxaliplatin (DRUG), Radiotherapy (RADIATION), Irinotecan (DRUG), Leucovorin Calcium (DRUG).
Who is sponsoring clinical trial NCT00068692?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00068692 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Rectal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Recurrent Rectal Carcinoma
All registered trials for this condition
Stage IIIA Rectal Cancer AJCC v7
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.